-       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - May 2024
    -  134 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                -       Report 
   - August 2023
    -  367 Pages 
    Global
   
   From       €2247EUR$2,500USD£1,971GBP 
                      The Arthralgia Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. It is composed of drugs used to treat arthralgia, which is a type of joint pain. These drugs are typically used to reduce inflammation and pain, and can be administered orally, topically, or through injection. Commonly used drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).
The Arthralgia Drug market is highly competitive, with    many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and AbbVie. Other companies include Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. Show Less   Read more